Show simple item record

dc.contributor.authorWong, KH
dc.contributor.authorPanek, R
dc.contributor.authorWelsh, L
dc.contributor.authorMcquaid, D
dc.contributor.authorDunlop, A
dc.contributor.authorRiddell, A
dc.contributor.authorMurray, I
dc.contributor.authorDu, Y
dc.contributor.authorChua, S
dc.contributor.authorKoh, D-M
dc.contributor.authorBhide, S
dc.contributor.authorNutting, C
dc.contributor.authorOyen, WJG
dc.contributor.authorHarrington, K
dc.contributor.authorNewbold, KL
dc.date.accessioned2016-09-28T11:01:06Z
dc.date.issued2016-12
dc.identifier.citationJournal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016, 57 (12), pp. 1843 - 1850
dc.identifier.issn0161-5505
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/128
dc.identifier.eissn1535-5667
dc.identifier.doi10.2967/jnumed.116.174433
dc.description.abstractThe objective of this study was to assess the predictive value of early assessment (after 1 cycle of induction chemotherapy [IC]) with 18 F-FDG PET/CT and diffusion-weighted (DW) MRI for subsequent response to radical chemoradiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC).Methods Twenty patients with stage III-IVa HNSCC prospectively underwent 18 F-FDG PET/CT and DW MRI before and 2 wk after each cycle of IC (first cycle, IC1; second cycle, IC2). Response was assessed 3 mo after completion of chemoradiotherapy with clinical examination, MRI, and 18 F-FDG PET/CT. Patients with persistent disease were classed as nonresponders. Changes in functional and molecular imaging parameters after IC1 were compared between responders and nonresponders with the Mann-Whitney U test. The significance threshold was set at a P value of less than 0.05.Results Responders showed a significantly greater reduction in metabolic tumor volume (P = 0.03) and total lesion glycolysis (P = 0.04) after IC1 than nonresponders. Responders also showed a tendency toward a larger but statistically nonsignificant increase in apparent diffusion coefficient after IC1. There was no significant difference in the changes from baseline between the IC1 and IC2 for all functional and molecular imaging parameters, indicating that most biologic response to IC measured by 18 F-FDG PET/CT and DW MRI was observed early after the first cycle of IC.Conclusion Our preliminary data indicate that the 18 F-FDG PET/CT-derived metabolic tumor volume or total lesion glycolysis, acquired after IC1, are early predictive biomarkers for ultimate response to subsequent chemoradiotherapy. These early biomarkers enable identification of patients at risk of treatment failure at an early time point, permitting treatment individualization and consideration of alternative strategies such as radiotherapy dose escalation or surgery.
dc.formatPrint-Electronic
dc.format.extent1843 - 1850
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectCarcinoma, Squamous Cell
dc.subjectHead and Neck Neoplasms
dc.subjectFluorodeoxyglucose F18
dc.subjectDiffusion Magnetic Resonance Imaging
dc.subjectTreatment Failure
dc.subjectPredictive Value of Tests
dc.subjectTime Factors
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectChemoradiotherapy
dc.subjectInduction Chemotherapy
dc.subjectMultimodal Imaging
dc.subjectPositron Emission Tomography Computed Tomography
dc.titleThe Predictive Value of Early Assessment After 1 Cycle of Induction Chemotherapy with 18F-FDG PET/CT and Diffusion-Weighted MRI for Response to Radical Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma.
dc.typeJournal Article
dcterms.dateAccepted2016-05-31
rioxxterms.versionofrecord10.2967/jnumed.116.174433
rioxxterms.licenseref.startdate2016-12
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal of nuclear medicine : official publication, Society of Nuclear Medicine
pubs.issue12
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume57
pubs.embargo.termsNo embargo
icr.researchteamTargeted Therapyen_US
icr.researchteamTranslational Molecular Imagingen_US
dc.contributor.icrauthorMurray,en
dc.contributor.icrauthorWong, Keeen
dc.contributor.icrauthorHarrington, Kevinen
dc.contributor.icrauthorKoh, Dow-Muen
dc.contributor.icrauthorOyen, Willemen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record